Literature DB >> 15536153

WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12.

Karl Balabanian1, Bernard Lagane, José Luis Pablos, Lysiane Laurent, Thierry Planchenault, Olivier Verola, Celeste Lebbe, Delphine Kerob, Alain Dupuy, Olivier Hermine, Jean-François Nicolas, Véronique Latger-Cannard, Danièle Bensoussan, Pierre Bordigoni, Françoise Baleux, Françoise Le Deist, Jean-Louis Virelizier, Fernando Arenzana-Seisdedos, Françoise Bachelerie.   

Abstract

The WHIM syndrome is a rare immunodeficiency disorder characterized by warts, hypogammaglobulinemia, infections, and myelokathexis. Dominant heterozygous mutations of the gene encoding CXCR4, a G-protein-coupled receptor with a unique ligand, CXCL12, have been associated with this pathology. We studied patients belonging to 3 different pedigrees. Two siblings inherited a CXCR4 mutation encoding a novel C-terminally truncated receptor. Two unrelated patients were found to bear a wild-type CXCR4 open reading frame. Circulating lymphocytes and neutrophils from all patients displayed similar functional alterations of CXCR4-mediated responses featured by a marked enhancement of G-protein-dependent responses. This phenomenon relies on the refractoriness of CXCR4 to be both desensitized and internalized in response to CXCL12. Therefore, the aberrant dysfunction of the CXCR4-mediated signaling constitutes a common biologic trait of WHIM syndromes with different causative genetic anomalies. Responses to other chemokines, namely CCL4, CCL5, and CCL21, were preserved, suggesting that, in clinical forms associated with a wild-type CXCR4 open reading frame, the genetic anomaly might target an effector with some degree of selectivity for the CXCL12/CXCR4 axis. We propose that the sustained CXCR4 activity in patient cells accounts for the immune-hematologic clinical manifestations and the profusion of warts characteristic of the WHIM syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15536153     DOI: 10.1182/blood-2004-06-2289

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  122 in total

1.  Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.

Authors:  Beili Wu; Ellen Y T Chien; Clifford D Mol; Gustavo Fenalti; Wei Liu; Vsevolod Katritch; Ruben Abagyan; Alexei Brooun; Peter Wells; F Christopher Bi; Damon J Hamel; Peter Kuhn; Tracy M Handel; Vadim Cherezov; Raymond C Stevens
Journal:  Science       Date:  2010-10-07       Impact factor: 47.728

Review 2.  Regulation of neutrophil trafficking from the bone marrow.

Authors:  Ryan B Day; Daniel C Link
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

3.  Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approach.

Authors:  Marco A C Neves; Sérgio Simões; M Luisa Sá e Melo
Journal:  J Comput Aided Mol Des       Date:  2010-10-20       Impact factor: 3.686

Review 4.  Neutrophils cascading their way to inflammation.

Authors:  Christian D Sadik; Nancy D Kim; Andrew D Luster
Journal:  Trends Immunol       Date:  2011-08-11       Impact factor: 16.687

5.  Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.

Authors:  Martin F M de Rooij; Annemieke Kuil; Willem Kraan; Marie José Kersten; Steven P Treon; Steven T Pals; Marcel Spaargaren
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

6.  MicroRNA126 contributes to granulocyte colony-stimulating factor-induced hematopoietic progenitor cell mobilization by reducing the expression of vascular cell adhesion molecule 1.

Authors:  Ombretta Salvucci; Kan Jiang; Paola Gasperini; Dragan Maric; Jinfang Zhu; Shuhei Sakakibara; Georgina Espigol-Frigole; Shushang Wang; Giovanna Tosato
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

Review 7.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

8.  A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.

Authors:  David H McDermott; Qian Liu; Daniel Velez; Lizbeeth Lopez; Sandra Anaya-O'Brien; Jean Ulrick; Nana Kwatemaa; Judy Starling; Thomas A Fleisher; Debra A Long Priel; Melissa A Merideth; Robert L Giuntoli; Moses O Evbuomwan; Patricia Littel; Martha M Marquesen; Dianne Hilligoss; Rosamma DeCastro; George J Grimes; Samuel T Hwang; Stefania Pittaluga; Katherine R Calvo; Pamela Stratton; Edward W Cowen; Douglas B Kuhns; Harry L Malech; Philip M Murphy
Journal:  Blood       Date:  2014-02-12       Impact factor: 22.113

9.  High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.

Authors:  Marlène Pasquet; Christine Bellanné-Chantelot; Suzanne Tavitian; Naïs Prade; Blandine Beaupain; Olivier Larochelle; Arnaud Petit; Pierre Rohrlich; Christophe Ferrand; Eric Van Den Neste; Hélène A Poirel; Thierry Lamy; Marie Ouachée-Chardin; Véronique Mansat-De Mas; Jill Corre; Christian Récher; Geneviève Plat; Françoise Bachelerie; Jean Donadieu; Eric Delabesse
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

Review 10.  Chemokine signaling in cancer: one hump or two?

Authors:  Joshua B Rubin
Journal:  Semin Cancer Biol       Date:  2008-10-17       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.